Philipp von Rosenstiel

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin et al. · The Lancet Neurology · 2014 · 815 citations

Disease Management, Relapsing-remitting Multiple Sclerosis, Disease Progression +7

Long-term effects of fingolimod in multiple sclerosis

Ludwig Kappos, Paul O’Connor, Ernst‐Wilhelm Radue et al. · Neurology · 2015 · 187 citations · Full text

Exacerbation of Apoptosis in the Dentate Gyrus of the Aged Rat by Dexamethasone and the Protective Role of Corticosterone

Ali Hassan, Philipp von Rosenstiel, Vladimir K. Patchev et al. · Experimental Neurology · 1996 · 179 citations

Medicine, Physiology, Dentate Gyrus +7

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

Jeffrey A. Cohen, Bhupendra Khatri, Frederik Barkhof et al. · Journal of Neurology Neurosurgery & Psychiatry · 2015 · 162 citations · Full text

Adjunctive brivaracetam for refractory partial-onset seizures

Jacqueline A. French, Costantino Costantini, Alan L. Brodsky et al. · Neurology · 2010 · 151 citations